Business Context and Reporting Period
This Form 8-K, dated July 14, 2023, reports a material definitive agreement entered into by Frequency Therapeutics, Inc. (the "Company") and Korro Bio, Inc. ("Korro Bio"). The filing details an Agreement and Plan of Merger under which a wholly-owned subsidiary of Frequency will merge with and into Korro Bio, with Korro Bio surviving as a wholly-owned subsidiary of Frequency.
Key Financial Metrics and Transaction Terms
- Equity Valuation: Korro Bio has been ascribed an aggregate equity value of approximately $325.6 million. Frequency's equity value will be determined based on its net cash at closing.
- Concurrent Financing: Korro Bio is consummating a financing with expected gross proceeds of approximately $117 million (minimum condition of $100 million) immediately prior to the merger effective time.
- Merger Consideration: Outstanding Korro Bio common stock, options, and warrants will convert into Frequency common stock based on a formula utilizing the respective equity values. Preferred stock will convert to common stock prior to the merger.
- Termination Fees:
- Korro Bio may be required to pay Frequency $4,000,000 upon termination under specified circumstances.
- Frequency may be required to pay Korro Bio $1,500,000 upon termination under specified circumstances.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or margin data for either company.
Material Changes and Governance
The primary material change is the proposed combination of the two entities. Upon closing, the Board of Directors of the combined company is expected to consist of seven members:
- One member designated by Frequency.
- Four members designated by Korro Bio.
- Two independent members.
Support agreements have been executed by holders of approximately 98% of Korro Bio's capital stock and 11.7% of Frequency's common stock to vote in favor of the merger. Lock-up agreements restrict share transfers for 180 days post-closing for key insiders and investors.
Guidance, Risks, and Contingencies
- Conditions to Closing: The merger is subject to stockholder approvals, regulatory clearances, the effectiveness of a Form S-4 registration statement, and the successful completion of the Concurrent Financing (minimum $100 million).
- Contingent Value Rights (CVRs): Frequency stockholders will receive one CVR for each share held if the Company's multiple sclerosis (MS) remyelination program assets are not disposed of prior to closing. CVRs entitle holders to contingent payments from future proceeds of the MS asset disposition, net of costs. There is no assurance payments will be made.
- Reverse Stock Split: Frequency stockholders will vote to amend the certificate of incorporation to effect a reverse stock split of outstanding shares.
- Risks: Risks include failure to obtain stockholder or regulatory approval, inability to integrate businesses, disruption of operations, and the uncertainty of the CVR payments. The filing includes a standard cautionary statement regarding forward-looking statements.
Investor Verification Checklist
- Verify the final equity value of Frequency at closing, as the exchange ratio depends on its net cash position.
- Confirm the successful closing of the Concurrent Financing to ensure the $100 million minimum condition is met.
- Review the upcoming Form S-4 Proxy Statement/Prospectus for detailed financial data and voting instructions.
- Assess the status of the MS Asset Disposition to understand the potential value of the Contingent Value Rights (CVRs).
- Monitor the timeline for stockholder votes and the November 14, 2023, termination deadline.